Axsome Therapeutics Inc [AXSM] stock prices are up 3.63% to $112.35 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AXSM shares have gain 9.11% over the last week, with a monthly amount glided 0.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on June 03, 2025, and set its price target to $185. On April 07, 2025, Jefferies initiated with a Buy rating and assigned a price target of $200 on the stock. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $176 on February 11, 2025. Mizuho reiterated its recommendation of a Outperform and reduced its price target to $122 on December 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on September 03, 2024, and assigned it a price target of $140. In a note dated August 06, 2024, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $95 to $106.
The stock price of Axsome Therapeutics Inc [AXSM] has been fluctuating between $72.21 and $139.13 over the past year. Currently, Wall Street analysts expect the stock to reach $189.33 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $112.35 at the most recent close of the market. An investor can expect a potential return of 68.52% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
The Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 432.16M for trailing twelve months, representing a surge of 61.95%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.63%, Pretax Profit Margin comes in at -0.64%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -3.64 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 109.29 points at the first support level, and at 106.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 115.04, and for the 2nd resistance point, it is at 117.73.
Ratios To Look Out For
It’s worth pointing out that Axsome Therapeutics Inc [NASDAQ:AXSM]’s Current Ratio is 2.03. Further, the Quick Ratio stands at 1.96, while the Cash Ratio is 1.23. Considering the valuation of this stock, the price to sales ratio is 12.80, the price to book ratio is 103.93.
Transactions by insiders
Recent insider trading involved Murdock Hunter R., General Counsel, that happened on Jun 20 ’25 when 7500.0 shares were sold. General Counsel, Murdock Hunter R. completed a deal on Jun 23 ’25 to sell 6014.0 shares. Meanwhile, Officer Murdock Hunter R. bought 6014.0 shares on Jun 23 ’25.
